• Conditions and diseases

  • Blood and immune system •
  • Cancer •
  • Cardiovascular •
  • Central nervous system •
  • Digestive system •
  • Ear and nose •
  • Endocrine, nutritional and metabolic •
  • Eye •
  • Gynaecology, pregnancy and birth •
  • Infectious diseases •
  • Injuries, accidents and wounds •
  • Mental health and behavioural conditions •
  • Mouth and dental •
  • Musculoskeletal •
  • Respiratory •
  • Skin •
  • Urogenital

• Public health

  • Accidents and injuries •
  • Alcohol •
  • Behaviour change •
  • Cancer •
  • Cardiovascular disease •
  • Child health •
  • Child social care •
  • Chronic illness •
  • Diabetes •
  • Drugs •
  • Environmental health •
  • Infectious diseases •
  • Maternal health •
  • Mental health •
  • Non-communicable diseases •
  • Obesity and diet •
  • Occupational health •
  • Older people •
  • Physical activity •
  • Sexual health •
  • Smoking and tobacco •
  • Transport •
  • Vaccine preventable diseases •
  • Working with and involving communities

• Treatments, Procedures and Devices

  • Bones and joint surgery •
  • Cardiovascular surgery •
  • Cardiovascular system drug treatments •
  • Clinical devices •
  • Diagnostic imaging •
  • Diagnostic procedures •
  • Digestive tract and other abdominal organs surgery •
  • Drug treatments •
  • Endocrine system and breast surgery •
  • Eye surgery •
  • Nervous system surgery •
  • Radiotherapy •
  • Screening •
  • Surgical procedures •
  • Therapeutic procedures •
  • Tissue and organ donation •
  • Urogenital surgery

• Guidance by type

  • Clinical Guidelines •
  • Technology appraisals •
  • Public health guidance •
  • Diagnostics guidance •
  • Interventional procedures guidance •
  • Medical technologies guidance •
  • Cancer service guidance •
  • Quality standards

• Guidance by date

  • View the guidance by date published

About NICE guidance Close

Navigation

• News

• News
• Features
• NICE newsletters and alerts
• Events
• Media centre
• NICE annual conference
• Guidance in Focus
• Podcasts
• Videocasts
• Meetings held in public

2007/006 NICE publishes final guidance on bevacizumab and cetuximab for the treatment of metastatic colorectal cancer

The National Institute for Health and Clinical Excellence (NICE) has today published final guidance on the use of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.

The guidance does not recommend the use of these drugs for first line therapy for metastatic colorectal cancer (bevacizumab) and therapy following the failure of an irinotecan containing chemotherapy regimen (cetuximab) and means that the joint appeal against the recommendations contained in the Final Appraisal Determination in respect of cetuximab by Bowel Cancer UK and Cancerbackup and the appeal by Merck Pharmaceuticals have not been upheld.

 

2007/006 NICE publishes final guidance on bevacizumab and cetuximab for the treatment of metastatic colorectal cancer 24 January 2007 (34.6Kb 12sec @ 28.8Kbps)

Adobe Acrobat reader required.

This page was last updated: 30 April 2009